Core Laboratories (CLB) Stock Forecast, Price Target & Predictions
CLB Stock Forecast
Core Laboratories stock forecast is as follows: an average price target of $25.00 (represents a 29.47% upside from CLB’s last price of $19.31) and a rating consensus of 'Hold', based on 4 wall street analysts offering a 1-year stock forecast.
CLB Price Target
The average price target for Core Laboratories (CLB) is $25.00 based on 1-year price targets from 4 Wall Street analysts in the past 3 months, with a price target range of $32.00 to $17.00. This represents a potential 29.47% upside from CLB's last price of $19.31.
CLB Analyst Ratings
According to 4 Wall Street analysts, Core Laboratories's rating consensus is 'Hold'. The analyst rating breakdown for CLB stock is 0 'Strong Buy' (0.00%), 0 'Buy' (0.00%), 3 'Hold' (75.00%), 1 'Sell' (25.00%), and 0 'Strong Sell' (0.00%).
Core Laboratories Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Jul 15, 2024 | Luke Lemoine | Piper Sandler | $17.00 | $21.78 | -21.95% | -11.96% |
| Feb 07, 2023 | - | Citigroup | $26.00 | $26.20 | -0.78% | 34.65% |
| May 02, 2022 | - | Morgan Stanley | $32.00 | $26.65 | 20.10% | 65.72% |
The latest Core Laboratories stock forecast, released on Jul 15, 2024 by Luke Lemoine from Piper Sandler, set a price target of $17.00, which represents a -21.95% decrease from the stock price at the time of the forecast ($21.78), and a -11.96% decrease from CLB last price ($19.31).
Core Laboratories Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 1 |
| Avg Price Target | - | - | $17.00 |
| Last Closing Price | $19.31 | $19.31 | $19.31 |
| Upside/Downside | -100.00% | -100.00% | -11.96% |
In the current month, the average price target of Core Laboratories stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Core Laboratories's last price of $19.31. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Jul 15, 2024 | Piper Sandler | Neutral | Neutral | Hold |
| Feb 07, 2023 | Citigroup | Neutral | Neutral | Hold |
| Jan 09, 2023 | Bank of America Securities | - | Neutral | Upgrade |
| Oct 06, 2022 | Citigroup | - | Neutral | Upgrade |
| Sep 26, 2022 | Morgan Stanley | Equal-Weight | Underweight | Downgrade |
| May 02, 2022 | Morgan Stanley | Equal-Weight | Equal-Weight | Hold |
Core Laboratories's last stock rating was published by Piper Sandler on Jul 15, 2024. The company gave CLB a "Neutral" rating, the same as its previous rate.
Core Laboratories Financial Forecast
Core Laboratories Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $128.36M | $127.57M | $125.97M | $120.90M | $115.30M | $125.14M | $117.98M | $118.75M | $108.38M | $113.75M | $105.38M | $115.74M | $152.40M | $156.78M | $173.20M |
| Avg Forecast | $140.87M | $140.79M | $139.68M | $137.06M | $139.12M | $138.53M | $134.33M | $130.59M | $132.49M | $134.16M | $132.85M | $124.13M | $128.00M | $129.81M | $131.25M | $126.18M | $130.03M | $126.08M | $121.46M | $113.01M | $122.42M | $122.68M | $119.53M | $110.51M | $109.19M | $109.76M | $115.91M | $152.37M | $155.95M | $171.64M |
| High Forecast | $143.69M | $143.61M | $142.47M | $139.80M | $141.90M | $141.30M | $137.01M | $133.85M | $135.14M | $134.73M | $132.85M | $124.13M | $129.20M | $134.33M | $133.87M | $128.71M | $132.63M | $126.08M | $121.46M | $113.01M | $122.42M | $122.68M | $119.53M | $110.51M | $109.19M | $109.76M | $115.91M | $152.37M | $155.95M | $171.64M |
| Low Forecast | $138.66M | $138.58M | $137.49M | $134.91M | $136.93M | $136.35M | $132.22M | $127.32M | $130.41M | $133.58M | $132.85M | $124.13M | $126.59M | $128.39M | $129.19M | $124.20M | $127.99M | $126.08M | $121.46M | $113.01M | $122.42M | $122.68M | $119.53M | $110.51M | $109.19M | $109.76M | $115.91M | $152.37M | $155.95M | $171.64M |
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 1 | 1 | 1 | 3 | 6 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 3 | 16 | 8 | 11 | 7 | 11 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.02% | 0.98% | 1.00% | 1.00% | 1.02% | 1.02% | 0.96% | 0.99% | 0.98% | 1.04% | 0.96% | 1.00% | 1.00% | 1.01% | 1.01% |
Core Laboratories's average Quarter revenue forecast for Jun 23 based on 3 analysts is $131.25M, with a low forecast of $129.19M, and a high forecast of $133.87M. CLB's average Quarter revenue forecast represents a 2.25% increase compared to the company's last Quarter revenue of $128.36M (Mar 23).
Core Laboratories EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 1 | 1 | 1 | 3 | 6 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 3 | 16 | 8 | 11 | 7 | 11 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $10.53M | $19.69M | $18.82M | $16.01M | $4.17M | $18.50M | $11.00M | $17.39M | $16.39M | $27.83M | $16.46M | $2.82M | $-103.61M | $26.63M | $36.42M |
| Avg Forecast | $20.50M | $20.49M | $20.33M | $19.95M | $20.25M | $20.16M | $19.55M | $19.01M | $19.28M | $19.53M | $19.34M | $5.54M | $18.63M | $18.89M | $19.10M | $5.03M | $20.35M | $18.35M | $17.68M | $4.57M | $17.82M | $17.86M | $17.40M | $13.87M | $15.89M | $15.97M | $16.87M | $-112.76M | $22.70M | $24.98M |
| High Forecast | $20.91M | $20.90M | $20.74M | $20.35M | $20.65M | $20.57M | $19.94M | $19.48M | $19.67M | $19.61M | $19.34M | $6.64M | $18.80M | $19.55M | $19.48M | $6.04M | $24.42M | $18.35M | $17.68M | $5.49M | $17.82M | $17.86M | $17.40M | $16.64M | $15.89M | $15.97M | $16.87M | $-90.21M | $22.70M | $24.98M |
| Low Forecast | $20.18M | $20.17M | $20.01M | $19.64M | $19.93M | $19.85M | $19.24M | $18.53M | $18.98M | $19.44M | $19.34M | $4.43M | $18.43M | $18.69M | $18.80M | $4.03M | $16.28M | $18.35M | $17.68M | $3.66M | $17.82M | $17.86M | $17.40M | $11.10M | $15.89M | $15.97M | $16.87M | $-135.31M | $22.70M | $24.98M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 2.09% | 0.97% | 1.03% | 0.91% | 0.91% | 1.04% | 0.62% | 1.00% | 1.18% | 1.75% | 1.03% | 0.17% | 0.92% | 1.17% | 1.46% |
3 analysts predict CLB's average Quarter EBITDA for Jun 23 to be $19.10M, with a high of $19.48M and a low of $18.80M. This is 81.50% upper than Core Laboratories's previous annual EBITDA (Mar 23) of $10.53M.
Core Laboratories Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 1 | 1 | 1 | 3 | 6 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 3 | 16 | 8 | 11 | 7 | 11 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $2.37M | $6.75M | $7.52M | $7.07M | $-1.84M | $2.79M | $874.00K | $8.06M | $8.11M | $13.54M | $2.96M | $-5.72M | $-108.42M | $10.33M | $23.73M |
| Avg Forecast | $15.98M | $15.63M | $15.04M | $14.20M | $13.85M | $13.39M | $12.22M | $11.15M | $11.06M | $11.67M | $9.36M | $-2.54M | $8.99M | $10.50M | $9.75M | $-2.31M | $2.96M | $7.27M | $6.54M | $-2.10M | $9.60M | $8.91M | $9.12M | $6.86M | $7.32M | $6.90M | $5.22M | $-117.99M | $17.76M | $23.24M |
| High Forecast | $16.40M | $16.04M | $15.43M | $14.57M | $14.21M | $13.74M | $12.54M | $11.44M | $11.95M | $11.83M | $9.37M | $-2.03M | $9.23M | $11.45M | $10.00M | $-1.85M | $3.55M | $7.27M | $6.54M | $-1.68M | $9.60M | $8.91M | $9.12M | $8.23M | $7.32M | $6.90M | $5.22M | $-94.39M | $17.76M | $23.24M |
| Low Forecast | $15.66M | $15.31M | $14.74M | $13.91M | $13.57M | $13.11M | $11.98M | $10.92M | $10.18M | $11.50M | $9.36M | $-3.05M | $8.09M | $8.59M | $9.55M | $-2.77M | $2.37M | $7.27M | $6.54M | $-2.52M | $9.60M | $8.91M | $9.12M | $5.49M | $7.32M | $6.90M | $5.22M | $-141.59M | $17.76M | $23.24M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -1.03% | 2.28% | 1.03% | 1.08% | 0.88% | 0.29% | 0.10% | 0.88% | 1.18% | 1.85% | 0.43% | -1.10% | 0.92% | 0.58% | 1.02% |
Core Laboratories's average Quarter net income forecast for Jun 23 is $9.75M, with a range of $9.55M to $10.00M. CLB's average Quarter net income forecast represents a 310.93% increase compared to the company's last Quarter net income of $2.37M (Mar 23).
Core Laboratories SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 1 | 1 | 1 | 3 | 6 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 3 | 16 | 8 | 11 | 7 | 11 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $16.33M | $8.72M | $10.00M | $6.85M | $12.54M | $10.93M | $15.12M | $9.67M | $8.46M | $-3.69M | $8.94M | $9.22M | $19.57M | $9.77M | $11.01M |
| Avg Forecast | $11.06M | $11.05M | $10.96M | $10.76M | $10.92M | $10.87M | $10.54M | $10.25M | $10.40M | $10.53M | $10.43M | $16.87M | $10.05M | $10.19M | $10.30M | $15.33M | $12.02M | $9.90M | $9.53M | $13.94M | $9.61M | $9.63M | $9.38M | $7.16M | $8.57M | $8.61M | $9.10M | $21.29M | $12.24M | $13.47M |
| High Forecast | $11.28M | $11.27M | $11.18M | $10.97M | $11.14M | $11.09M | $10.75M | $10.51M | $10.61M | $10.58M | $10.43M | $20.24M | $10.14M | $10.54M | $10.51M | $18.40M | $14.42M | $9.90M | $9.53M | $16.73M | $9.61M | $9.63M | $9.38M | $8.59M | $8.57M | $8.61M | $9.10M | $25.55M | $12.24M | $13.47M |
| Low Forecast | $10.88M | $10.88M | $10.79M | $10.59M | $10.75M | $10.70M | $10.38M | $9.99M | $10.24M | $10.48M | $10.43M | $13.49M | $9.94M | $10.08M | $10.14M | $12.27M | $9.62M | $9.90M | $9.53M | $11.15M | $9.61M | $9.63M | $9.38M | $5.73M | $8.57M | $8.61M | $9.10M | $17.03M | $12.24M | $13.47M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.07% | 0.73% | 1.01% | 0.72% | 0.90% | 1.14% | 1.57% | 1.03% | 1.18% | -0.43% | 1.04% | 1.01% | 0.92% | 0.80% | 0.82% |
Core Laboratories's average Quarter SG&A projection for Jun 23 is $10.30M, based on 3 Wall Street analysts, with a range of $10.14M to $10.51M. The forecast indicates a -36.92% fall compared to CLB last annual SG&A of $16.33M (Mar 23).
Core Laboratories EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 1 | 1 | 1 | 3 | 6 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 3 | 16 | 8 | 11 | 7 | 11 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $0.05 | $0.14 | $0.16 | $0.15 | $-0.04 | $0.06 | $0.02 | $0.17 | $0.18 | $0.30 | $0.07 | $-0.13 | $-2.44 | $0.23 | $0.53 |
| Avg Forecast | $0.33 | $0.33 | $0.31 | $0.30 | $0.29 | $0.28 | $0.26 | $0.23 | $0.23 | $0.24 | $0.20 | $0.16 | $0.19 | $0.22 | $0.20 | $0.16 | $0.19 | $0.15 | $0.14 | $0.07 | $0.20 | $0.19 | $0.19 | $0.13 | $0.15 | $0.14 | $0.11 | $0.32 | $0.37 | $0.49 |
| High Forecast | $0.34 | $0.34 | $0.32 | $0.30 | $0.30 | $0.29 | $0.26 | $0.24 | $0.25 | $0.25 | $0.20 | $0.16 | $0.19 | $0.24 | $0.21 | $0.16 | $0.20 | $0.15 | $0.14 | $0.07 | $0.20 | $0.19 | $0.19 | $0.13 | $0.15 | $0.14 | $0.11 | $0.32 | $0.37 | $0.49 |
| Low Forecast | $0.33 | $0.32 | $0.31 | $0.29 | $0.28 | $0.27 | $0.25 | $0.23 | $0.21 | $0.24 | $0.20 | $0.16 | $0.17 | $0.18 | $0.20 | $0.16 | $0.19 | $0.15 | $0.14 | $0.07 | $0.20 | $0.19 | $0.19 | $0.13 | $0.15 | $0.14 | $0.11 | $0.32 | $0.37 | $0.49 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.32% | 0.72% | 1.05% | 1.10% | -0.60% | 0.30% | 0.10% | 0.91% | 1.34% | 1.98% | 0.46% | -1.18% | -7.58% | 0.62% | 1.10% |
According to 3 Wall Street analysts, Core Laboratories's projected average Quarter EPS for Jun 23 is $0.20, with a low estimate of $0.20 and a high estimate of $0.21. This represents a 300.63% increase compared to CLB previous annual EPS of $0.05 (Mar 23).
Core Laboratories Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| RES | RPC | $5.68 | $10.00 | 76.06% | Hold |
| NR | Newpark Resources | $6.57 | $11.00 | 67.43% | Buy |
| OIS | Oil States | $4.72 | $7.50 | 58.90% | Hold |
| DNOW | NOW | $11.87 | $18.00 | 51.64% | - |
| NGS | Natural Gas Services Group | $19.90 | $28.00 | 40.70% | Buy |
| CHX | ChampionX | $28.43 | $38.33 | 34.82% | Buy |
| NOV | NOV | $15.39 | $20.67 | 34.31% | Buy |
| MRC | MRC Global | $12.20 | $16.00 | 31.15% | Buy |
| CLB | Core Laboratories | $19.31 | $25.00 | 29.47% | Hold |
| NEX | NexTier Oilfield Solutions | $10.61 | $13.50 | 27.24% | Hold |
| WHD | Cactus | $61.36 | $54.00 | -11.99% | Hold |
| OII | Oceaneering | $25.45 | $21.00 | -17.49% | Buy |
CLB Forecast FAQ
Is Core Laboratories a good buy?
No, according to 4 Wall Street analysts, Core Laboratories (CLB) is considered a 'Hold'. The rating consensus is based on 0 'Strong Buy' and 0 'Buy' recommendations, accounting for 0% of CLB's total ratings.
What is CLB's price target?
Core Laboratories (CLB) average price target is $25 with a range of $17 to $32, implying a 29.47% from its last price of $19.31. The data is based on 4 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Core Laboratories stock go up soon?
According to Wall Street analysts' prediction for CLB stock, the company can go up by 29.47% (from the last price of $19.31 to the average price target of $25), up by 65.72% based on the highest stock price target, and down by -11.96% based on the lowest stock price target.
Can Core Laboratories stock reach $30?
CLB's highest twelve months analyst stock price target of $32 supports the claim that Core Laboratories can reach $30 in the near future.
What are Core Laboratories's analysts' financial forecasts?
Core Laboratories's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $542.56M (high $554.06M, low $532.83M), average EBITDA is $78.97M (high $80.64M, low $77.55M), average net income is $50.62M (high $51.93M, low $49.58M), average SG&A $42.59M (high $43.49M, low $41.82M), and average EPS is $1.06 (high $1.09, low $1.04). CLB's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $558.41M (high $569.57M, low $549.64M), average EBITDA is $81.27M (high $82.9M, low $80M), average net income is $60.86M (high $62.44M, low $59.62M), average SG&A $43.83M (high $44.71M, low $43.14M), and average EPS is $1.27 (high $1.31, low $1.25).
Did the CLB's actual financial results beat the analysts' financial forecasts?
Based on Core Laboratories's last annual report (Dec 2022), the company's revenue was $489.74M, which missed the average analysts forecast of $490.58M by -0.17%. Apple's EBITDA was $58.68M, missing the average prediction of $60.95M by -3.72%. The company's net income was $19.45M, beating the average estimation of $14.67M by 32.60%. Apple's SG&A was $38.12M, missing the average forecast of $45.39M by -16.02%. Lastly, the company's EPS was $0.42, missing the average prediction of $0.55 by -23.61%. In terms of the last quarterly report (Mar 2023), Core Laboratories's revenue was $128.36M, beating the average analysts' forecast of $126.18M by 1.72%. The company's EBITDA was $10.52M, beating the average prediction of $5.03M by 109.17%. Core Laboratories's net income was $2.37M, missing the average estimation of $-2.308M by -202.84%. The company's SG&A was $16.33M, beating the average forecast of $15.33M by 6.51%. Lastly, the company's EPS was $0.0509, missing the average prediction of $0.16 by -68.13%